Source: PharmiWeb

Polarispharma: Polaris Group Presents Results for Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 Plus FOLFOX in Hepatocellular Carcinoma

Polaris Group Presents Results for Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 Plus FOLFOX in Hepatocellular Carc...Polaris Group

Read full article »
Polarispharma's Competitors | Polarispharma's News | Polarispharma's Financials
Stay up-to-date with the latest news on Polaris
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Steve J.P. Hsu's photo - CEO of Polaris

CEO

Steve J.P. Hsu

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on Polaris